Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NCB-02
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Enema, Oral
01
Overview
NCB-02 is a standardized preparation of curcuminoids, with curcumin being its active ingredient, known for its anti-inflammatory and antioxidant properties. It has been investigated for its potential in treating mild-to-moderate distal ulcerative colitis and type 2 diabetes mellitus. Its mechanism of action involves the down-regulation of NFkappa-B and iNOS, as well as the reduction of oxidative stress and inflammatory cytokines like IL-6 and TNFalpha.
- Other names
- standardized curcumin preparationstandardized preparation of curcuminoids
02
Targets
IL-6 (Interleukin 6)NOS2 (Nitric Oxide Synthase 2)
Beyond the preview
Go deeper on NCB-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NCB-02.